Subscribe to RSS
DOI: 10.5935/2526-8732.20190014
Year in Review 2018 by the Brazilian Gastrointestinal Tumors Group - GTG: Gastrointestinal Tumors
Revisão Ano 2018 pelo Grupo Brasileiro de Tumores Gastrointestinais - GTG: Tumores Gastrointestinais
Financial support: none to declare.
ABSTRACT
In 2018, there were some important trials presented over multiple international meetings. The objective of this article is to summarize the most important and practice changing studies in gastrointestinal oncology this year. Some studies in gastroesophageal, pancreatic, colorectal and anal canal have been selected, including adjuvant therapy in pancreatic cancer, immunotherapy in metastatic gastroesophageal cancer, as well as strategies in regorafenib dose escalation and the role of hyperthermic intraperitoneal chemotherapy in metastatic colorectal.
RESUMO
Em 2018, houve alguns estudos importantes apresentados em múltiplas reuniões internacionais. O objetivo deste artigo é resumir os mais importantes estudos e mudança da prática oncológica gastrointestinal este ano. Alguns estudos gastroesofágicos, pancreáticos, colorretais e do canal anal foram selecionados, incluindo terapia adjuvante em câncer pancreático, imunoterapia em câncer gastroesofágico metastático, bem como estratégias de escalonamento da dose de regorafenibe e o papel da quimioterapia intraperitoneal hipertérmica em câncer colorretal metastático.
Keywords:
Gastrointestinal neoplasms - Stomach neoplasms - Esophageal neoplasms - Pancreatic neoplasms - Colorectal neoplasms - Anal canal.Descritores:
Neoplasias gastrointestinais - Neoplasias estomacais - Neoplasias esofágicas - Neoplasias pancreáticas - Neoplasias colorretais - Canal anal.Publication History
Received: 05 December 2018
Accepted: 27 June 2019
Article published online:
11 July 2019
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Anelisa K. Coutinho, Gabriel Prolla, Gustavo dos Santos Fernandes, Heber Salvador, Renata D'Alpino Peixoto, Rui F. Weschenfelder. Year in Review 2018 by the Brazilian Gastrointestinal Tumors Group - GTG: Gastrointestinal Tumors. Brazilian Journal of Oncology 2019; 15: e-20190014.
DOI: 10.5935/2526-8732.20190014
-
REFERENCES
- Siegel RL. et al Cancer Statistics, 2018. CA Cancer J Clin 2018; jan; 68 (01) 7-30
- Bray F. et al Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; nov; 68 (06) 394-424
- Fuchs CS. et al Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018; may; 4 (05) e180013
- Conroy T. et al Unicancer GI PRODIGE24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. J Clin Oncol 2018; jun; 36 (Suppl 18): LBA4001
- Bekaii-Saab. et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and preemptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol 2018; jun; 29 (Suppl 5): O-014
- Lemery S. et al First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med 2017; oct; 377 (15) 1409-1412
- Lenz H-J. et al Durable clinical benefit with Nivolumab plus low-dose Ipilimumab (IPI) as first-line therapy in microsatellite instability high/ mismatch repair deficient metastatic colorectal cancer. ESMO 2018 Congress; 2018. aug; 22; Munich, Germany: ESMO. LBA18_PR
- Quenet F. et al A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018; jun; 36 (Suppl 18): LBA3503
- Goere D. et al Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP - NTC01226394). J Clin Oncol 2018; jun; 36 (Suppl 15): 3531
- Hong YS. et al Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. J Clin Oncol 2018; jun; 36 (Suppl 15): 3501
- Kim S. et al Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 2018; aug; 19 (08) 1094-1106
- Rao S. et al InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5- FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial. ESMO 2018 Congress; 2018. aug; 22; Munich, Germany: ESMO. LBA21